About: Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy Model

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy Model Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy Model
Creator	Hayashi, Michie Hayashi, Shusaku Kadowaki, Makoto Nagata, Yuka Yamamoto, Takeshi
Source	PMC
abstract	Oral immunotherapy (OIT) has been considered a promising approach for food allergies (FAs). However, the current OIT strategy is limited in terms of the long-term efficacy and safety. We have previously demonstrated that kakkonto, a traditional Japanese herbal medicine, suppresses the occurrence of allergic symptoms in a murine model of ovalbumin (OVA)-induced FA, which is attributed to the induction of the Foxp3(+) CD4(+) regulatory T cells. In this study, we established an OIT model using the FA mice with already established allergic symptoms and determined whether kakkonto could improve the efficacy of OIT. The OIT method consisted of initially administrating a very small amount of OVA and slowly increasing the amount. Allergic symptoms decreased in the OIT-treated FA mice. OIT significantly downregulated Th2 immune response-related gene expression in the FA mouse colon, and decreased the level of mouse mast cell protease-1, a marker of mast cell degranulation in the FA mouse plasma. Moreover, the concomitant use of kakkonto significantly enhanced the effectiveness of OIT on the allergic symptoms, and the combination therapy further suppressed the Th2 immune responses and the mast cell degranulation. In addition, OIT significantly increased the population of Foxp3(+) CD4(+) regulatory T cells in the FA mouse colon, and this population was further increased by OIT in combination with kakkonto. Furthermore, the combined therapy with kakkonto reduced the expression of RA-degrading enzyme CYP26B1 mRNA in the FA mouse colon. These findings indicated that the combination of OIT with kakkonto represents a promising approach for FA treatment.
has issue date	2017-01-20(xsd:dateTime)
bibo:doi	10.1371/journal.pone.0170577
bibo:pmid	28107533
has license	cc-by
sha1sum (hex)	d940acd1f38f4b26cf2a7aeb4212f6854450ed0a
schema:url	https://doi.org/10.1371/journal.pone.0170577
resource representing a document's title	Improvement of Therapeutic Efficacy of Oral Immunotherapy in Combination with Regulatory T Cell-Inducer Kakkonto in a Murine Food Allergy Model
has PubMed Central identifier	PMC5249179
has PubMed identifier	28107533
schema:publication	PLoS One
resource representing a document's body	covid:d940acd1f38f4b26cf2a7aeb4212f6854450ed0a#body_text
is schema:about of	named entity 'ESTABLISHED' named entity 'COMBINATION THERAPY' named entity 'TREATMENT' named entity 'FINDINGS' named entity 'SMALL AMOUNT' named entity 'MODEL OF' named entity 'GENE EXPRESSION' named entity 'ORAL IMMUNOTHERAPY' named entity 'ALLERGIC SYMPTOMS' named entity 'INITIALLY' named entity 'ENHANCED' named entity 'TH2 IMMUNE RESPONSE' named entity 'INDUCTION' named entity 'MODEL' named entity 'MICE' named entity 'STUDY' named entity 'PREVIOUSLY' named entity 'CD4' named entity 'IMMUNE RESPONSES' named entity 'USING' named entity 'MURINE' named entity 'PLASMA' named entity 'Foxp3' named entity 'effectiveness' named entity 'CD4' named entity 'colon' named entity 'efficacy' named entity 'allergic symptoms' named entity 'enhanced' named entity 'promising' named entity 'downregulated' named entity 'plasma' named entity 'Regulatory T' named entity 'IMPROVEMENT' named entity 'THERAPEUTIC EFFICACY' covid:arg/d940acd1f38f4b26cf2a7aeb4212f6854450ed0a named entity 'REGULATORY T CELL' named entity 'COMBINED THERAPY' named entity 'RELATED' named entity 'CURRENT' named entity 'VERY SMALL' named entity 'DETERMINED' named entity 'EFFECTIVENESS' named entity 'TH2' named entity 'CONSIDERED' named entity 'TERMS' named entity 'ADDITION' named entity 'DEMONSTRATED' named entity 'FOOD ALLERGIES' named entity 'STRATEGY' named entity 'FOXP3' named entity 'JAPANESE' named entity 'ENZYME' named entity 'MURINE' named entity 'COMBINATION' named entity 'MODEL' named entity 'ORAL IMMUNOTHERAPY' named entity 'FOOD ALLERGY' named entity 'APPROACH' named entity 'MOUSE MAST CELL' named entity 'DECREASED' named entity 'SUPPRESSES' named entity 'TRADITIONAL' named entity 'METHOD' named entity 'CYP26B1' named entity 'MOUSE COLON' named entity 'CONCOMITANT' named entity 'USE OF' named entity 'LEVEL' named entity 'SAFETY' named entity 'REGULATORY T CELLS' named entity 'INCREASING' named entity 'INCREASED' named entity 'INDUCED' named entity 'PROTEASE' named entity 'OCCURRENCE' named entity 'MOUSE'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software